DURHAM, N.C., November 5, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced the appointment of Jason Mieding to the role of Chief Operating Officer (COO), a newly created position that reflects the growth of the organization over the past 22 months.
MedPharm Inks Deal to Support Global Pharmaceutical Company with Commercial Site Transfer
DURHAM, N.C., October 1, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced that it has signed a new agreement with a global pharmaceutical company to support the commercial site transfer and commercial manufacturing of their branded specialty topical pharmaceutical product.
MedPharm and Palvella Therapeutics Named CPHI Awards 2026 Finalists
MedPharm and Palvella Therapeutics have been named finalists in the True Partnership Excellence category at the CPHI Awards 2026, recognizing their multi-year collaboration in the development of QTORIN™ rapamycin.
MedPharm Expands End-to-End Proteomic Analysis Capabilities with Olink® Certification
DURHAM, N.C., August 20, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced that it has become an Olink® Certified Service Provider (CSP), making it the first Olink CSP in the Carolinas and one of only three in the Southeastern United States.
Meet MedPharm at CPHI Milan 2026
We’re excited to be exhibiting at CPHI Milan 2026, one of the pharmaceutical industry’s leading global events. If you’re attending, we’d love the opportunity to connect and discuss how MedPharm can help advance your topical and transepithelial drug development programs. This year, we’re also proud to be joined by our strategic partner, Purna, showcasing our integrated transatlantic capabilities from development through commercial manufacturing.
Event Details
📍 Booth: 12C69 (Hall 12)
📍 Location: Milan, Italy
📅 Dates: Tuesday, 6 October – Thursday, 8 October 2026
Whether you’re looking for support with formulation development, analytical testing, in vitro performance testing, clinical trial manufacturing, scale-up, or commercial manufacturing, our team will be available to discuss your development goals and demonstrate how our integrated approach helps de-risk programs from concept through commercialization.
Together, MedPharm and Purna provide a seamless partnership that combines scientific expertise in topical and transepithelial drug development with commercial manufacturing capabilities, helping sponsors move programs confidently from concept to market.
Stop by our booth to meet our scientists and business development team, learn about our latest capabilities, and discover how MedPharm and Purna can support your next development program.
We look forward to seeing you in Milan!
Purna and MedPharm to Establish Trans-Atlantic Partnership to Serve Global Clients
Boston, MA, February 12, 2026 – Ampersand Capital Partners, a private equity firm specializing in growth investments in the life sciences and healthcare sectors, today announced its acquisition of Purna Pharmaceuticals, a trusted provider of development and manufacturing services for liquid and semi-solid dosage forms in support of pharmaceutical industry customers.
MedPharm Welcomes Palvella Therapeutics’ Positive Topline Results from Its Phase 3 Study of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
DURHAM, N.C., March 17, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today welcomed the news that its partner, Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), recently announced positive topline results from its Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), an investigational therapy underdevelopment for the treatment of microcystic lymphatic malformations (microcystic LMs).
MedPharm Announces Successful U.S. FDA Inspection of its CGMP Commercial Manufacturing Facility In Durham, North Carolina
DURHAM, N.C., January 7, 2026 – MedPharm, a global leader in topical and transdermal contract drug development and manufacturing, today announced that its topical drug product manufacturing facility in Durham has successfully completed a U.S. Food and Drug Administration (FDA) inspection for commercial manufacture of drug products.
